Enzo Biochem. has been granted a patent for methods and kits to diagnose viral diseases, including idiopathic pulmonary fibrosis and certain cancers, by detecting virus-specific elements. The patent also covers monitoring disease progression and therapeutic efficacy, as well as treatment methods and prevention strategies for viral infections. GlobalData’s report on Enzo Biochem gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Enzo Biochem, Cancer treatment biomarkers was a key innovation area identified from patents. Enzo Biochem's grant share as of July 2024 was 57%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for diagnosing and treating viral diseases
The granted patent US12061198B2 outlines a novel composition designed for the detection of Herpesvirus saimiri within human lung tissue specimens. The primary component of this composition is a viral nucleic acid target sequence that is hybridized to a non-radioactively labeled nucleic acid. This labeled nucleic acid contains one or more sequences that are complementary to the Herpesvirus saimiri genome. The non-radioactive label can take various forms, including fluorescent, chemiluminescent, hapten, chromogenic, or energy transfer pair elements. Importantly, the labeled nucleic acid must be fully complementary to a sequence of at least 20 contiguous nucleotides from specified sequence identifiers (ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO: 14) and is specifically utilized in isolated lung tissue specimens.
Further claims within the patent detail specific characteristics of the composition. For instance, the viral nucleic acid target sequence may directly correspond to the nucleotide sequence of Herpesvirus saimiri. Additionally, the non-radioactively labeled nucleic acid can be biotin-labeled or may include locked nucleic acid (LNA) oligonucleotides. The patent also specifies that the labeled nucleic acid can incorporate nucleotide sequences from other designated sequence identifiers (SEQ ID: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8). This composition presents a significant advancement in the field of viral detection, particularly in the context of human lung tissue analysis.
To know more about GlobalData’s detailed insights on Enzo Biochem, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
